Quoin reports FY2024 net loss $9.0M; cash $14.1M; positive QRX003 whole-body data in Netherton

Quoin Pharmaceuticals, Ltd.

Cash of $14.1M at Dec 31, 2024 expected to fund operations into Q2 2026.
Net loss FY2024 $9.0M vs $8.7M; Q4 loss $2.3M vs $2.0M year ago.
First pediatric patient on whole-body QRX003 showed skin healing in 2 weeks, discontinued all prior meds, zero sleep disturbances.
FDA cleared whole-body QRX003 study; to be led by Dr. Amy Paller at Northwestern University.
Filed patent applications for topical rapamycin formulations targeting rare dermatological diseases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.